Most Recent Articles by Bryant Furlow
In this question-and-answer session, Cancer Therapy Advisor asked Dr Wildes about the management of multiple myeloma among older patients.
Two children with recurrent metastatic, TFE3 fusion-positive RCC that expressed MET experienced "prolonged disease control" following treatment with cabozantinib.
The FDA granted atezolizumab accelerated approval for first-line treatment of advanced or metastatic urothelial carcinoma regardless of PD-L1 expression status.
Total dietary consumption of fresh fruit — and citrus fruit consumption in particular — is associated with a modestly lower risk of developing prostate cancer.
With vaccine treatment, 4 patients had not progressed for more than 4.9 years and 3 patients had not progressed more than 7 years post-diagnosis.
More Articles by Bryant Furlow
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Bladder-sparing Therapy Outcomes Similar to Cystectomy in Bladder Cancer
- Prostate Cancer Risk and Fruit Intake
- In Focus: Atezolizumab for Non-small Cell Lung Cancer
- Q&A With Tanya Wildes, MD: Managing Multiple Myeloma in Older Patients
- PSA Density More Accurate Than PSA for Predicting Prostate Cancer
- Everolimus, Exemestane Safety Profile Same With Prior Chemo in Breast Cancer
- Lung Cancer: Timing May Affect EGFR mutation-related ctDNA Test Results
- Adding Bevacizumab to Chemo May Prolong Survival in Recurrent Ovarian Cancer
- Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD
- Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL